Predictive Model for Idiopathic Multicentric Castleman Disease Supporting Treatment Decisions

被引：1
|
作者：
Fang, Xiaosheng [1 ,2 ]
Sun, Zhongling [3 ]
Xu-Monette, Zijun Y. [1 ,4 ]
Young, Ken H. [1 ,4 ]
机构：
[1] Duke Univ, Med Ctr, Dept Pathol, Hematopathol Div, Durham, NC 27710 USA
[2] Shandong First Med Univ, Shandong Prov Hosp, Dept Hematol, Jinan, Shandong, Peoples R China
[3] Peoples Hosp Zhaoyuan City, Dept Neurol, Zhaoyuan, Shandong, Peoples R China
[4] Duke Canc Inst, Durham, NC USA
来源：
ONCOLOGIST | 2021年 / 26卷 / 01期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1002/onco.13605
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：4 / 6
页数：3
相关论文
共 50 条
  • [21] Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease?
    Fujimoto, Shino
    Sakai, Tomoyuki
    Kawabata, Hiroshi
    Kurose, Nozomu
    Yamada, Sohsuke
    Takai, Kazue
    Aoki, Sadao
    Kuroda, Junya
    Ide, Makoto
    Setoguchi, Keigo
    Tsukamoto, Norifumi
    Iwao-Kawanami, Haruka
    Kawanami, Takafumi
    Mizuta, Shuichi
    Fukushima, Toshihiro
    Masaki, Yasufumi
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (09) : 975 - 983
  • [22] Idiopathic multicentric Castleman disease: bringing order to chaos
    Leitch, Heather A.
    LANCET HAEMATOLOGY, 2020, 7 (03): : E180 - E181
  • [23] Targeting the mTOR pathway in idiopathic multicentric Castleman disease
    Stern, Robert M.
    Berliner, Nancy
    JOURNAL OF CLINICAL INVESTIGATION, 2019, 129 (10): : 4086 - 4088
  • [24] Increased mTOR activation in idiopathic multicentric Castleman disease
    Arenas, Daniel J.
    Floess, Katherine
    Kobrin, Dale
    Pai, Ruth-Anne Langan
    Srkalovic, Maya B.
    Tamakloe, Mark-Avery
    Rasheed, Rozena
    Ziglar, Jasira
    Khor, Johnson
    Parente, Sophia A. T.
    Pierson, Sheila K.
    Martinez, Daniel
    Wertheim, Gerald B.
    Kambayashi, Taku
    Baur, Joseph
    Teachey, David T.
    Fajgenbaum, David C.
    BLOOD, 2020, 135 (19) : 1673 - 1684
  • [25] Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease
    Fajgenbaum, David C.
    Kurzrock, Razelle
    IMMUNOTHERAPY, 2016, 8 (01) : 17 - 26
  • [26] Alveolar Hemorrhage in Idiopathic Multicentric Castleman's Disease
    Huang, Lingtong
    Zheng, Xia
    Huang, Xiaohan
    Wang, Lijun
    Fang, Xueling
    He, Guojun
    Tang, Meng
    Shi, Huixian
    Cai, Hongliu
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 208 (05) : 613 - 615
  • [27] Adrenalitis and anasarca in idiopathic multicentric Castleman's disease
    Chen, Luke Y. C.
    Skinnider, Brian F.
    Wilson, Don
    Fajgenbaum, David C.
    LANCET, 2021, 397 (10286): : 1749 - 1749
  • [28] Cytokine pathways in the pathogenesis of idiopathic Multicentric Castleman Disease
    Uhlfelder, D.
    Schaefer, H.
    Blanfeld, M.
    Andruszewski, D.
    Schelmbauer, C.
    Gaida, M.
    Waisman, A.
    Mufazalov, I
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2023, 53 : 136 - 136
  • [29] How We Manage Idiopathic Multicentric Castleman Disease
    Brandstadter, Joshua D.
    Fajgenbaum, David C.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (09) : 564 - 571
  • [30] Characterizing Mortality Associated with Idiopathic Multicentric Castleman Disease
    Pierson, Sheila K.
    Kanhai, Karan
    Bagg, Adam
    Alapat, Daisy
    Lim, Megan S.
    Lechowicz, Mary Jo
    Srkalovic, Gordan
    Uldrick, Thomas S.
    van Rhee, Frits
    Fajgenbaum, David C.
    BLOOD, 2021, 138
12345